TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6365194

Group type: EXPERIMENTAL
Intervention: QU.A.RT. method (quadrantectomy, axillary dissection, radiotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 0
Study: 30027597

Group type: EXPERIMENTAL
Intervention: In-Plane Guidance (IPFA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Electromagnetic Needle Tracking (ENT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Freehand
Number of subjects: 18
Study: 30498351

Group type: EXPERIMENTAL
Intervention: 3-monthly paliperidone palmitate (PP3M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: once-monthly paliperidone palmitate (PP1M)
Number of subjects: 0
Study: 26845640

Group type: EXPERIMENTAL
Intervention: Multifaceted peer-group based intervention including FP communication skills training, antibiotic prescribing agreements, and quarterly feedback figures.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (matched PTAM groups).
Number of subjects: 8
Study: 24552366

Group type: EXPERIMENTAL
Intervention: Low GI diet (45-50% carbohydrate, 30-35% fat, 15-20% protein)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional Chinese diet (55-60% carbohydrate, 25-30% fat, 10-15% protein)
Number of subjects: 104
Study: 22152974

Group type: EXPERIMENTAL
Intervention: Intensified N-terminal brain natriuretic peptide-guided HF therapy
Number of subjects: 566

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 566
Study: 19129205

Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/day
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 17453362

Group type: EXPERIMENTAL
Intervention: Dose-escalated chemotherapy (de FEC)
Number of subjects: 129

Group type: COMPARATOR
Intervention: FEC and HDCT+BMS
Number of subjects: 129
Study: 15610835

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 1, men)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 2, women)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Fentanyl 1.5 microg/kg and thiopental 2 mg/kg (Group 3, women)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Baseline values
Number of subjects: 83
Study: 11594574

Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 0
Study: 9701719

Group type: EXPERIMENTAL
Intervention: 4 x 50 microgram TRH administered intravenously at 22.00, 23.00, 24.00, and 01.00 h
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo administered intravenously
Number of subjects: 7
Study: 8053243

Group type: EXPERIMENTAL
Intervention: VVI-R pacing
Number of subjects: 27
Study: 2686604

Group type: EXPERIMENTAL
Intervention: Dietary intervention to alter triglyceride levels
Number of subjects: 0
Study: 31356512

Group type: EXPERIMENTAL
Intervention: Hip Extension Exercise (HEE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nordic Hamstring Exercise (NHE)
Number of subjects: 24
Study: 30596450

Group type: EXPERIMENTAL
Intervention: Verbal working memory training (Study 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Verbal working memory training (Study 2)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Active control group (Study 1)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Active control group (Study 2)
Number of subjects: 41
Study: 31585343

Group type: EXPERIMENTAL
Intervention: 10-week internet-delivered exposure therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 140
Study: 27998910

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 55
Study: 25441960

Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet (eSLD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Diet (CD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tablet computer usage
Number of subjects: 20
Study: 23550808

Group type: EXPERIMENTAL
Intervention: 50 mg dehydroepiandrosterone (DHEA) added to EE/DRSP COC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (without DHEA) in EE/DRSP COC
Number of subjects: 0
Study: 21166602

Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 83
Study: 19623023

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 24
Study: 16687697

Group type: EXPERIMENTAL
Intervention: Safe water systems (SWS)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of SWS
Number of subjects: 196

Group type: COMPARATOR
Intervention: Hypothetical scenario based on another SWS trial in Kenya
Number of subjects: 196
Study: 12600797

Group type: EXPERIMENTAL
Intervention: diclofenac-K 12.5mg
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: diclofenac-K 25mg
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: ibuprofen 400mg
Number of subjects: 620

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 620
Study: 10929920

Group type: EXPERIMENTAL
Intervention: Zafirlukast 10 mg BID
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Zafirlukast 5 mg BID
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg BID
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Zafirlukast 40 mg BID
Number of subjects: 714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study: 8644030

Group type: EXPERIMENTAL
Intervention: Calcium antagonists (nifedipine, verapamil, diltiazem)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Overall treatment efficacy
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Calcium antagonists treatment
Number of subjects: 160
Study: 1455885

Group type: EXPERIMENTAL
Intervention: Cholangiography
Number of subjects: 115

Group type: COMPARATOR
Intervention: No cholangiography (Control)
Number of subjects: 115
Study: 3901672

Group type: EXPERIMENTAL
Intervention: mianserin 30 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: clonidine 0.150 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30859984

Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 441mg
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 882mg
Number of subjects: 432
Study: 30836809

Group type: EXPERIMENTAL
Intervention: Low-frequency airborne ultrasound therapy (Glybetac)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 58
Study: 27717532

Group type: EXPERIMENTAL
Intervention: Collaborative goal-setting intervention using a low‐literacy aid
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Patient-driven action plans
Number of subjects: 302
Study: 26413529

Group type: EXPERIMENTAL
Intervention: Depression group (n = 29)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 59
Study: 23430026

Group type: EXPERIMENTAL
Intervention: Amniotomy group
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 320
Study: 21457793

Group type: EXPERIMENTAL
Intervention: PVAC group (duty-cycled bipolar and unipolar radiofrequency)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 3D group (point-by-point ablation)
Number of subjects: 80
Study: 18835735

Group type: EXPERIMENTAL
Intervention: Oral 17beta‐oestradiol valerate 2mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 17943521

Group type: EXPERIMENTAL
Intervention: Harm minimisation intervention
Number of subjects: 4636

Group type: COMPARATOR
Intervention: Standard abstinence-based intervention
Number of subjects: 4636
Study: 15230858

Group type: EXPERIMENTAL
Intervention: IFN-alpha nl after prednisolone priming
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: IFN-alpha 2a
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 210
Study: 14745340

Group type: EXPERIMENTAL
Intervention: Levofloxacine
Number of subjects: 275

Group type: COMPARATOR
Intervention: Comparer antibiotics (amoxicillin-clavulanic acid, amoxicillin, ceftriaxone, ceftriaxone plus cefuroxime +/- erythromycin)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Comparer antibiotics
Number of subjects: 275
Study: 9696721

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: glycine (13 g/day; placebo)
Number of subjects: 10
Study: 8026089

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Age at operation
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: History of earache prior to operation
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Parental smoking habits
Number of subjects: 222
Study: 2626417

Group type: EXPERIMENTAL
Intervention: Three-part intervention (lecture, chart-based reminder, biweekly feedback)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control groups (Group II and Group III)
Number of subjects: 36
Study: 30738593

Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation using perfluorooctyl bromide
Number of subjects: 0
Study: 28139023

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 25
Study: 26167739

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 0
Study: 23052568

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biperiden + Rivastigmine
Number of subjects: 0
Study: 22125782

Group type: EXPERIMENTAL
Intervention: 50 mg of prednisolone daily for 14 days
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 19095857

Group type: EXPERIMENTAL
Intervention: Single-shot spinal (SSS) anesthesia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) anesthesia
Number of subjects: 30
Study: 16229022

Group type: EXPERIMENTAL
Intervention: Qigong treatment group (n = 32)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group receiving no additional intervention (n = 24)
Number of subjects: 56
Study: 15526246

Group type: EXPERIMENTAL
Intervention: Amiodarone 400 mg daily plus irbesartan 300 mg daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Amiodarone 400 mg daily plus irbesartan 150 mg daily
Number of subjects: 90

Group type: COMPARATOR
Intervention: Amiodarone 400 mg daily
Number of subjects: 90
Study: 11139948

Group type: EXPERIMENTAL
Intervention: Pilsicainide (PLS) 100-150 mg single oral dose
Number of subjects: 72

Group type: COMPARATOR
Intervention: Disopyramide (DISO) 2 mg/kg infusion (maximum dose = 100 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Pilsicainide (PLS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Disopyramide (DISO)
Number of subjects: 72
Study: 9313630

Group type: EXPERIMENTAL
Intervention: Sulodexide (administered IM for ten days and orally for fifty days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcium Heparin (subcutaneous for sixty days)
Number of subjects: 30
Study: 8398303

Group type: EXPERIMENTAL
Intervention: DTIC plus recombinant interferon‐alfa2a (IFN)
Number of subjects: 152

Group type: COMPARATOR
Intervention: DTIC alone
Number of subjects: 152
Study: 7039840

Group type: EXPERIMENTAL
Intervention: Cinoxacin 250 mg, four times a day
Number of subjects: 58

Group type: COMPARATOR
Intervention: Nitrofurantoin 100 mg, four times a day
Number of subjects: 58
Study: 30781485

Group type: EXPERIMENTAL
Intervention: 2.5 g of flavanol‐rich cocoa powder ingested with a diabetic‐suitable breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Microcrystalline cellulose ingested with a diabetic‐suitable breakfast
Number of subjects: 12
Study: 27434189

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study: 26174294

Group type: EXPERIMENTAL
Intervention: Propofol at an estimated brain concentration of 0.90 μg ml(‐1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 24450487

Group type: EXPERIMENTAL
Intervention: Extended combined oral contraceptives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frovatriptan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22803758

Group type: EXPERIMENTAL
Intervention: Critical reflection guidelines
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Feedback on both content and reflective ability
Number of subjects: 149

Group type: COMPARATOR
Intervention: Definition of critical reflection only
Number of subjects: 149
Study: 19443528

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg
Number of subjects: 6184

Group type: COMPARATOR
Intervention: Salmeterol (SAL) 50 microg
Number of subjects: 6184

Group type: EXPERIMENTAL
Intervention: Combination therapy (SFC)
Number of subjects: 6184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6184
Study: 17479928

Group type: EXPERIMENTAL
Intervention: Actions presented with varying distance from a routine
Number of subjects: 0
Study: 16494979

Group type: EXPERIMENTAL
Intervention: Functional knee bracing
Number of subjects: 30

Group type: COMPARATOR
Intervention: No bracing
Number of subjects: 30
Study: 12644803

Group type: EXPERIMENTAL
Intervention: D‐DBA technique (DBA applied immediately after preparations)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: I‐DBA technique (DBA applied just before luting)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No DBA technique (no bonding agent used)
Number of subjects: 120
Study: 10471420

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE)
Number of subjects: 1415

Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 1415
Study: 7570509

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (3-4 times a week for 6 weeks, 20-30 minutes per session)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 45
Study: 1937998

Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dilevalol 600 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dilevalol (all doses)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 6130532

Group type: EXPERIMENTAL
Intervention: Atropine (0.4 or 0.8 mg subcutaneous injections)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bethanechol (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 16,16-dimethyl prostaglandin E2 (DmPGE2, 7 to 140 ng/kg intravenous over five minutes)
Number of subjects: 0
Study: 31296475

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health education group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29023535

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CES, 6% carbohydrate)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte‐protein solution (CEPS, 2% protein plus 4% carbohydrate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Noncaloric sweetened placebo (PLA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte‐protein solution (CEPS)
Number of subjects: 11
Study: 26234894

Group type: EXPERIMENTAL
Intervention: Two minutes CPR
Number of subjects: 119

Group type: COMPARATOR
Intervention: Five cycles CPR (30:2)
Number of subjects: 119
Study: 23782555

Group type: EXPERIMENTAL
Intervention: EPO 150 IU/kg body weight
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 21452945

Group type: EXPERIMENTAL
Intervention: Self-generated action effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Congruent effect priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incongruent or neutral effect stimuli
Number of subjects: 0
Study: 19770662

Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard priming
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: RAP
Number of subjects: 120
Study: 17057609

Group type: EXPERIMENTAL
Intervention: TDF + FTC + EFV
Number of subjects: 517

Group type: COMPARATOR
Intervention: ZDV/3TC + EFV
Number of subjects: 517
Study: 12960117

Group type: EXPERIMENTAL
Intervention: 800 mg EGCG once/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 400 mg EGCG twice/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 800 mg EGCG as Polyphenon E once/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 400 mg EGCG as Polyphenon E twice/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo once/day
Number of subjects: 40
Study: 11115219

Group type: EXPERIMENTAL
Intervention: Rofecoxib 12.5 mg once daily
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg once daily
Number of subjects: 736

Group type: COMPARATOR
Intervention: Ibuprofen 800 mg three times daily
Number of subjects: 736

Group type: COMPARATOR
Intervention: Diclofenac 50 mg three times daily
Number of subjects: 736
Study: 9039546

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: Rifabutin + Ethambutol
Number of subjects: 382
Study: 1394826

Group type: EXPERIMENTAL
Intervention: M-VAC therapy (methotrexate, vinblastine, adriamycin, and cisplatin)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: M-VAC therapy
Number of subjects: 86
Study: 3871883

Group type: EXPERIMENTAL
Intervention: Propranolol 5 mg every 6 hours orally (n = 82)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (n = 82)
Number of subjects: 164
Study: 30416083

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg Q4W
Number of subjects: 1926

Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg Q8W
Number of subjects: 1926

Group type: COMPARATOR
Intervention: Placebo (previous trials)
Number of subjects: 1926
Study: 29996933

Group type: EXPERIMENTAL
Intervention: Personalised relaxation intervention practiced nightly for 4 weeks.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Personalised relaxation intervention (active intervention).
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 128
Study: 27107010

Group type: EXPERIMENTAL
Intervention: Functional endoscopic sinus surgery (FESS) with superior turbinate biopsy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS) only (control group)
Number of subjects: 131
Study: 25048506

Group type: EXPERIMENTAL
Intervention: BIS-guided sedation with propofol and remifentanil
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group monitored by the Modified Observer's Assessment of Alertness and Sedation scale
Number of subjects: 180
Study: 22901973

Group type: EXPERIMENTAL
Intervention: Hormone therapy for 6 months
Number of subjects: 86
Study: 20116285

Group type: EXPERIMENTAL
Intervention: Gadoxetic acid-enhanced MR imaging
Number of subjects: 36

Group type: COMPARATOR
Intervention: Four-phase multi-detector row computed tomography (CT)
Number of subjects: 36
Study: 17667568

Group type: EXPERIMENTAL
Intervention: Suxamethonium
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 111
Study: 16052045

Group type: EXPERIMENTAL
Intervention: rFSH 150 IU/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: rFSH 225 IU/day
Number of subjects: 63
Study: 11573752

Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT) from dietitians using a NCEP based lowering protocol
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual Care (UC) from physicians
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 90
Study: 9758087

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (cand.cil.) 8 mg o.i.d. (increased to 16 mg o.i.d. if necessary)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (cand.cil.) 8-16 mg o.i.d. for 12 weeks
Number of subjects: 161
Study: 7522510

Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) based chemotherapy or chemoimmunotherapy
Number of subjects: 136
Study: 2978286

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) [alpha‐human ANF (99‐126)]
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% (w/v) NaCl solution (saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31859433

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham-TEA
Number of subjects: 30
Study: 29777953

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous electrolysis
Number of subjects: 50

Group type: COMPARATOR
Intervention: Manual therapy and exercise
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 27998002

Group type: EXPERIMENTAL
Intervention: rBet v 1-FV allergen immunotherapy (AIT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56